A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 800
- Population
- ALL · 50 Years
- Duration
- 2025-12-05 to 2026-08-30
- Intervention
- IBI302 8mg dose
- Comparator
- Not reported
- Outcomes measured
- Proportion of participants whose best corrected visual acuity (BCVA) of the study eye decreased by less than 15 letters…; The changes in BCVA from baseline at each visit — Baseline，Weeks 4，8，12，16，20，24，28，32，36，40，44，48 and 52; Proportion of patients with BCVA improvement of ≥0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52 — Week52; Proportion of participants with a decrease in BCVA of >0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52 — Wee…; The change in central subfield thickness of the macula measured by OCT from the baseline at week 52 — Week52; Proportion of participants with IRF/SRF/Pigment epithelial detachment (PED) on OCT at Week 52 — Week52; Change in choroidal neovascularization (CNV) area on fundus fluorescein angiography (FFA) at week 52 compared to baseli…; Change in CNV leakage area on FFA at week 52 compared to baseline — Week52; Proportion of participants with new-onset MA on OCT at Week 52 — Week52; Proportion of new-onset fibrosis on color fundus photography (CFP) at Week 52 — Week52; Change in MA area on OCT from baseline at Week 52 — Week52; Change in fibrosis area and maximum lesion diameter on CFP from baseline at Week 52 — Week52; The incidence rate, correlation with the studied drugs, and severity of ocular and systemic adverse events (AE), treatm…; The production of anti-drug antibodies in the serum — Day0、Week4、Week16、Week32、Week48、Week52
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.